Resilient or Resistant: Pandemic Crisis and Early Observations of Different Preventive Capabilities from Cumulativeness of Scientific Research Points of View

As the world learned first-hand how the catastrophic Covid-19 virus infection affected public health and then the economy, many countries deployed their accumulated medical-related scientific and technological knowledge to safeguard public health. While many nations deployed resistant measures, a few strove to develop vaccines and inoculate their populations. In this study, we generally postulate that there are two groups of countries that are committed to research which is useful for preventive measures during an epidemic crisis. The first comprises countries that are endowed with resistant capability from the scientific research point of view. The second comprises nations endowed with resilient capability to develop vaccine candidates and achieve mass vaccination for lasting immunity against the virus. In this study, we resorted to publishing and patenting data for two scientific research categories. With the publication records, we observed that there are a few resistant nations – and their persistent research in public health coincided with their success in containing the Covid-19 outbreak in 2020. Countries such as the US and China are found resilient in our analysis. They pursued research in the field of experimental medicine – the crucial field in vaccine science – and their patenting records are evident. They produced timely vaccine candidates and succeeded in inoculating a significant share of their population. This study provided many imperative leads to understand what make a nation “resilient” and a significant step towards understanding the capabilities in deploying preventive measures